Update: 01 February 2019

Sevuparin is a new compound based on the commonly used blood thinner, heparin. It is able to restore blood flow and prevent obstruction of small blood vessels due to its anti-adhesive and anti-inflammatory characteristics.

Received Orphan Drug Designation by FDA and EMA.

A multi-centre, phase II, randomized, double-blind, placebo-controlled study to explore efficacy and safety of sevuparin infusion (over 2 – 7 continuous days) for the management acute vaso-occlusive crisis (VOC) in adolescent and adult patients with SCD is currently ongoing.

  • Study locations include: Netherlands, Turkey, Lebanon, Bahrain, Oman, Saudi Arabia and Jamaica.
  • The study is expected to end in March 2019.

Sevuparin has received rare paediatric disease designation from the FDA (April 2018). This will provide the developing company a number of incentives and facilitations towards further study of the safety and efficacy of the drug and marketing authorisation and exclusivity.

In addition, phase 1 clinical study will be launched in the US to test the safety of subcutaneous administration of sevuparin for the treatment of SCD.  The FDA has accepted sevuparin’s investigational new drug application.